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Introduction: Soft tissue sarcomas are heterogeneous tumors that are difficult to treat. Up to 50 percent of
patients develop metastatic disease and require systemic chemotherapy. Ifosfamide and doxorubicin are the two
most active agents.
Case presentation: A 33-year-old Caucasian woman presented to our facility with a metastatic myxoid
liposarcoma. Our patient was initially treated with surgery and radiation therapy, but experienced three recurrences
during a six-year period, the first and the last occurring while our patient was pregnant. The first recurrence, which
occurred two years after diagnosis and was localized in the left cervical and right axillary region, was treated with
surgery followed by chemotherapy. Molecular analysis of this tumor showed a t(12,16) + translocation resulting in a
FUS-DDIT3 or EWSR1-DDIT3 fusion. Three years later our patient experienced a second recurrence in the left
supraclavicular fossa, upper thoracic and anterior mediastinum, which was treated with surgery alone. Eight months
later, during the second pregnancy, our patient experienced a third recurrence as a large cervical mass that was
treated, upon pregnancy, with trabectedin (1.5mg/m2/24-hour continuous infusion) for a total of 12 cycles. At that
time a computed tomography scan showed long-term partial response with excellent treatment tolerability.
Conclusions: This case report illustrates the potential therapeutic activity of trabectedin in patients with myxoid
liposarcoma.Introduction
Soft tissue sarcomas (STS) are heterogeneous tumors
that are difficult to treat. Up to 50 percent of patients
develop metastatic disease and require systemic chemo-
therapy. Ifosfamide and doxorubicin are the two most
active agents (response rates: 10 to 25 percent) [1].
Other alternative drugs have also been tested, with re-
sponse rates less than 10 percent. Recently, trabectedin,
which binds to the deoxyribonucleic acid (DNA) minor
groove, has demonstrated significant activity in phase II
studies in patients with STS, particularly those with leio-
myosarcomas and liposarcomas (LPS), leading to its ap-
proval for this indication in the European Union [2].
Myxoid liposarcoma (ML) accounts for one-third of lipo-
sarcomas and represents a morphologic continuum
encompassing myxoid and myxoid/round cell variants, the
latter characterized by an extent of round cell components* Correspondence: irenezarcos@hotmail.com
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reproduction in any medium, provided the orgreater than five percent [3]. ML is associated with a
chromosomal translocation resulting in FUS-CHOP or
EWS-CHOP fusion proteins. The high response rates
achieved with trabectedin in ML suggest a selective mech-
anism of action in this translocation-related sarcoma,
representing a potential target for the development of more
effective therapies. Additionally, early radiological changes
in ML tumor tissue often precede tumor shrinkage, which
may be delayed. Therefore, it seems important to integrate
both density and size in the response evaluation [4].
Here, we present the case of a patient with metastatic
LPS who achieved a prolonged partial response (PR)
with trabectedin.Case presentation
A 33-year-old Caucasian woman was diagnosed in 2006
with a localized myxoid LPS of the right thigh that was
treated with compartmental resection of the right quad-
riceps, with histopathological results showing a 10.7cm
low-grade ML (well differentiated, mitotic activity: <10
and <50 percent of necrosis), with infiltration of marginsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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without the presence of residual tumor in the margins.
Subsequently, she received adjuvant treatment with ex-
ternal radiotherapy to a dose of 70Gy. Two years later,
while pregnant, she noted a mass in her left cervical and
right axillary region, which proved to be a metastatic
low-grade LPS (Figure 1). Molecular analysis of this
tumor showed a t(12,16) + translocation resulting in a
FUS-DDIT3 or EWSR1-DDIT3 fusion. Our patient
underwent negative margin resection followed by adju-
vant chemotherapy with ifosfamide and epirubicin for
six months. Three years later, the disease recurred with
lesions in the left supraclavicular fossa (6.5×3.5cm) and
upper thoracic and anterior mediastinum (4.5×5.0cm).
The lesions were resected with no further treatment.
Eight months later, during her second pregnancy, our pa-
tient noted a mass in her left cervical area. She delayed
consultation for a few months until the baby was born
and eventually presented with a large cervical mass that
compressed the supra-aortic and carotid vessels and
extended caudally to occupy the upper portion of the
right hemi-thorax. There was also a second mass in the
left pleural space; tumor size was 9×5cm (Figure 2A,B).
Our patient was given trabectedin (1.5mg/m2/24-hour
continuous infusion) and after four cycles a significant
clinical improvement in her dyspnea and pain was noted.
A magnetic resonance imaging (MRI) scan showed a 50
percent reduction in the left supraclavicular mass, im-
provement in the chest lesion and resolution of theFigure 1 Histology of myxoid liposarcoma. Low magnification image o
prominent capillary pattern ((A), hematoxylin and eosin stain, original magn
showing uniform oval tumor cells and prominent, branching capillary patte
and eosin stain, original magnification ×100); branching capillary pattern st
some multi-vacuolated lipoblasts ((D), hematoxylin and eosin stain, originalpleural effusion. This was considered stable disease by
RECIST (Response Evaluation Criteria In Solid Tumors)
criteria and a PR according to the criteria of Choi et al.
[5]. She continued treatment for four additional cycles
with complete response in the neck mass and significant
reduction in the mediastinal and pleural lesions. A com-
puted tomography scan after 12 cycles demonstrated a
long-term PR according to RECIST criteria (Figure 2C,
D). Our patient remained asymptomatic with good treat-
ment tolerability (only two episodes of grade 2 and 3
neutropenia in cycles 3 and 4, respectively).
Discussion
ML accounts for one-third of liposarcomas and represents
a morphologic continuum encompassing myxoid and
myxoid/round cell variants, the latter characterized by an
extent of round cell components greater than five percent
[6]. The molecular hallmark of ML is the presence of
FUS-CHOP fusion proteins, with surgery and radioche-
motherapy the standard therapy for localized ML. Surgery
must include a wide excision with negative margins (R0).
While 1cm has been selected as a cut-off point in some
studies, it is important to realize that the margin can be
minimal in the case of resistant anatomical barriers, such
as muscular fasciae, periosteum and perineurium. Wide
excision followed by radiation therapy is standard treat-
ment in high-grade, deep lesions, >5cm. In the case of
low-grade, deep, >5cm soft tissue sarcoma, radiation ther-
apy should be discussed in a multidisciplinary fashion,f myxoid liposarcoma showing a variable number of adipocytes and a
ification ×50); myxoid liposarcoma with relatively low cellularity
rn with variable numbers of non-atypical adipocytes ((B), hematoxylin
aining with CD34 ((C), original magnification ×100); and presence of
magnification ×600).
Figure 2 Computed tomography scan of the thoracic region, before (A,B) and after (C,D) treatment with trabectedin (12 cycles).
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expected sequelae versus the histological aggressiveness.
Overall, radiation therapy has been shown to improve
local control, but not overall survival. Radiation therapy
should be administered post-operatively, with the best
technique available, at a dose of 50 to 60Gy, with fractions
of 1.8 to 2Gy, possibly with boosts up to 66Gy depending
on presentation and quality of surgery. Alternatively,
radiotherapy may be carried out pre-operatively, normally
using a dose of 50Gy. Intra-operative radiation therapy
(IORT) and brachytherapy are also options for selected
cases [3]. In our patient’s case, adjuvant treatment with ex-
ternal radiotherapy was considered even though she had a
low-grade LPS because of its size (10cm) and because ad-
equate margins could not be achieved. Our patient did
not receive adjuvant chemotherapy. The results of some
studies have shown that adjuvant chemotherapy might
improve, or at least delay, distant and local recurrence in
high-risk patients. However, a final demonstration of effi-
cacy is lacking. It is also unknown whether adjuvant
chemotherapy may be especially beneficial in specific sub-
groups. Therefore, adjuvant chemotherapy is not a stand-
ard treatment in adult-type soft tissue sarcomas. Clinical
practice guidelines propose adjuvant chemotherapy as an
option for high-risk individual patients, which includes
those having a >G1, deep, >5cm tumor [6].
Our patient experienced three recurrences during a six-
year period; two of them were managed with complete ex-
cision and the first was followed by adjuvant chemotherapy
with ifosfamide and epirubicin for six months. Clinicalguidelines recommend treating extrapulmonary disease re-
currence with chemotherapy as standard. However, in
selected cases, surgery of potentially resectable metastases
may be offered as an option following a multidisciplinary
evaluation, taking into consideration the site(s) and the
natural history of the disease in the individual patient.
Standard chemotherapy is based on anthracyclines as first-
line treatment [4,6].
Only a few cases of recurrent LPS have been reported
during pregnancy to date, and no solid evidence of an
increased incidence or a worse outcome has been demon-
strated. Trabectedin has shown activity in patients with
STS with a response rate of eight percent and a 47 percent
one-year survival. In a phase II study focused on patients
with leiomyosarcomas and LPS, the agent demonstrated a
14-month median survival that is superior to the expected
12 months seen with historical controls [7]. One issue in
assessing the activity of new agents in STS is the criteria for
response. Tumor size may increase or remain stable in
responding patients because of necrosis, bleeding and myx-
oid degeneration. For this reason, new criteria integrating
tumor size and tumor density have been proposed. Molecu-
lar analysis of this tumor showed a t(12,16) + translocation
resulting in a FUS-DDIT3 or EWSR1-DDIT3 fusion that
has been related in pre-clinical studies with the activity of
trabectedin in myxoid LPS [4].
Conclusions
This case report highlights the activity of trabectedin on
myxoid LPS with (12,16) + translocation resulting in a
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local and post-operative chemotherapy.
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